Gómez-Almaguer David
Servicio de Hematología, Hospital Universitario, UANL, Monterrey, N.L. México.
Hematology. 2012 Apr;17 Suppl 1:S25-7. doi: 10.1179/102453312X13336169155213.
Immune thrombocytopenic purpura is characterized by antibody-mediated destruction of platelets and suboptimal platelet production. Initially the treatment of ITP includes corticosteroids, IgG-anti-D, and intravenous immunoglobulins. Splenectomy and monoclonal antibodies are usually considered for refractory and chronic ITP patients. There are new data suggesting that early administration of rituximab is important, and this antibody has been used as first-line therapy in adults. In this concise review the role of rituximab and other monoclonal antibodies is analyzed. These agents have the capability of sparing splenectomy and possibly curing the disease in some patients.
免疫性血小板减少性紫癜的特征是抗体介导的血小板破坏和血小板生成不足。最初，ITP的治疗包括使用皮质类固醇、抗D免疫球蛋白和静脉注射免疫球蛋白。脾切除术和单克隆抗体通常用于难治性和慢性ITP患者。有新数据表明早期使用利妥昔单抗很重要，这种抗体已被用作成人的一线治疗药物。在这篇简要综述中，分析了利妥昔单抗和其他单克隆抗体的作用。这些药物有避免脾切除术并可能治愈部分患者疾病的能力。
